News
We send the latest information from SMC Laboratories.
Drug Efficacy Study in the STAM™ Model Published in Translational Oncology
SMC is proud to announce that Kurume University (JPN) has published the results of their study using our STAM&…
SMC attend BIO One-on-One Partnering™ in Bio Asia Taiwan!
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One PartneringTM i…
SMC announces Presentation of New Data at the 29th conference of The Japanese Society for the Research of Hepatic Cells.
Today, we are pleased to announce the acceptance of our abstract on our NASH-hepatocellular carcinoma (HCC) mo…
GN Corporation publication in Journal of Clinical and Experimental Hepatology
SMC announces that GN Corporation Clinical and Experimental Hepatology (Japan) has published the results of a …
Esperion Therapeutics's publication in Cell Metabolism
SMC announces that Esperion Therapeutics (MI, USA) has published the results of a study using STAM™ …
Potential NASH biomarker in NASH-HCC model
We would like to introduce the data for a serological marker from our NASH model (STAM™ model). Hepatoce…
Drug efficacy studies in NASH mouse model
We would like to introduce a study published by our client using our proprietary non-alcoholic steatohepatitis…
Introducing our new model: DDC-induced liver injury model
We introduce the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced liver injury model*, a well-known mod…
Reserve a non-clinical pharmacology consultation with us at BIO KOREA 2022!
We will join BIO KOREA 2022 International Convention, one of the biggest bio-health conventions in Asia. BIO K…
kk
We would like to introduce a study published by our client using our proprietary non-alcoholic steatohepatitis…